-+ 0.00%
-+ 0.00%
-+ 0.00%

Biotech announced that it recently received a notice from the European Medicines Agency that Gotenfia® has received positive opinions from the EMA Human Medicines Commission. The CHMP recommended that the European Commission approve the marketing of gotenfia® for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, and ulcerative colitis.

Zhitongcaijing·12/12/2025 07:49:00
Listen to the news
Biotech announced that it recently received a notice from the European Medicines Agency that Gotenfia® has received positive opinions from the EMA Human Medicines Commission. The CHMP recommended that the European Commission approve the marketing of gotenfia® for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, and ulcerative colitis.